Owkin’s Post

💡We are delighted to share the highlight impressions of the first AI Forum from Pharma to Pharma. 💡 It was a great experience that provided over 70 participants with insights and knowledge from presenters working in pharma. With over 50 companies in attendance, this event marked the beginning of an exciting new chapter in the evolving world of AI in pharma. Together, we created a valuable new platform for discussing topics related to AI in the pharmaceutical industry. This AI - Forum from June 11th, 2024 marks the start of an ongoing exchange. Check out the highlight video to get insights from the forum. Stay tuned for the next AI events to come. #artificialintelligence #pharma #shqa #ffi #aiforum

Jeanne Hecht, CEO and Chairwoman of Lexitas Pharma Services and esteemed member of 20/20 Onsite's Industry and Scientific Advisory Board, recently participated in a dynamic panel exploring the latest market trends for CROs. The discussion highlighted key topics such as the importance of specialization, ensuring diversity in clinical trials, and leveraging AI to enhance efficiency. The panel also addressed demands from pharmaceutical companies for expedited and high-quality trials. Congratulations, Jeanne, on your contributions to this important conversation. We look forward to hearing more of your insights and advancements. Dive into the key takeaways from the session:https://hubs.ly/Q02K_1NQ0 #CROs #LifeScience #TA #AI #ClinicalResearch

The landscape of #artificialintelligence is undergoing a seismic shift. The recent AI Forum in Switzerland by shqa swiss health quality association and FFI Ventures, held on June 11th, 2024, brought together over 70 participants from more than 50 companies to explore this transformative era. This gathering wasn't just about discussing AI. It was about navigating the revolutionary impact of generative AI in pharma. Presenters from the industry shared initial insights, illuminating how generative AI has an impact in Pharma and to its stakeholders. The forum marked the dawn of a new era, where AI isn't just a tool, but a collaborative partner in pharmaceutical innovation. We've only scratched the surface of generative AI's potential in pharma. This event is the first step in an ongoing journey of discovery and collaboration. Stay connected for future AI events as we continue to explore this rapidly evolving field. The future of pharma is being rewritten by AI, and we're at the forefront of this exciting transformation. Thanks to @shqa providing such a great platform to discuss the disruptive nature of #genAI.

𝐋𝐢𝐯𝐞 𝐐&𝐀 𝐚𝐥𝐞𝐫𝐭! 🚨 - 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫 𝟏𝟖, 𝟓 𝐏𝐌 𝐂𝐄𝐒𝐓 Join us for an exclusive live Q&A session where you can dive into the dynamic world of artificial intelligence in the pharmaceutical industry. We will unpack the realities and myths of AI’s role in pharma, guiding attendees through the transformative potential and current implementations of AI technologies. You can register for free at the following link: https://lnkd.in/egBG7eqM See you there!

In March 2024, John Rountree, Managing Director of Novasecta, facilitated Chatham-House-Rules discussion for senior executives in the biotech and pharmaceutical sectors, focusing on how firms can make the most of AI for their R&D efforts. This report summarises insights from the workshop. With transparency, realism, and a truly multi-disciplinary and cross-functional mindset, AI has great potential in pharmaceutical R&D. The best is yet to come. Read more here: https://lnkd.in/e4su9hzh

Can AI unlock $60-110 billion annually for the pharmaceutical industry? At the 5th Annual Pharma AI Summit in London, TrialAssure joined industry leaders to discuss how generative AI is revolutionizing everything from early drug development to personalized patient care. The key takeaway? Scaling AI is no longer optional—it’s essential for staying ahead in a rapidly evolving industry. Curious about the insights shared at the summit? Explore our full recap: https://loom.ly/2NOZ4KI #AI #GenerativeAI #Pharma #DrugDevelopment #ClinicalTrials

𝐋𝐢𝐯𝐞 𝐐&𝐀 𝐚𝐥𝐞𝐫𝐭! 🚨 - 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫 𝟏𝟖, 𝟓 𝐏𝐌 𝐂𝐄𝐒𝐓 Join us for an exclusive live Q&A session where you can dive into the dynamic world of artificial intelligence in the pharmaceutical industry. We will unpack the realities and myths of AI’s role in pharma, guiding attendees through the transformative potential and current implementations of AI technologies. You can register for free at the following link: https://lnkd.in/egBG7eqM See you there!

Interesting article on Gen AI in Pharma from Mckinsey. Generative AI in the pharmaceutical industry | McKinsey. https://lnkd.in/ehKysxdf Highlights the really big customer insight opportunity in Medical that we at KAI Conversations are already exploiting alongside commercial optimisation with a number of Top 20 global pharma businesses. The hype vs reality pieces highlights the real practical difficulties and why using GenAI alone isn't enough.

revolution: hope: hype: Pharma: AI:

Our Chief Medical Officer Sheuli Porkess was privileged to contribute to this fantastic discussion, facilitated by John Rountree of Novasecta last month. Along with senior executives in the biotech and pharmaceutical sectors, the discussion explored the potential for AI to support Research and Development of new pharmaceutical interventions. A key area where the potential of AI has yet to be fully realised is the opportunity to help increase diversity of participation in clinical trials through identification of patient populations and cohorts that have high risk of disease progression, reflecting key co-morbidities. This is becoming possible, as it is across all the functions of pharmaceutical R&D, informed by real world patient, and health economic, data. A key takeaway from the discussion was that harnessing of AI's full potential requires an increasingly conscious cross-functional, multi-diciplinary approach to make this a reality - which Precisia Clinical Risk Analytics stands ready to support.